SAB Biotherapeutics (SABS) Stock Price, News & Analysis

Company Overview

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Key Stats

• Today's Range: $1.72 to $1.82
• 50-Day Range: $1.60 to $1.98
• 52-Week Range: $1.00 to $5.01
• Volume: 14,060 shs
• Average Volume: 67,087 shs
• Market Capitalization: $16.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.25
• Consensus Rating: Buy

SAB Biotherapeutics Stock Analysis - MarketRank™

SAB Biotherapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 390th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($3.69) to ($2.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SAB Biotherapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SAB Biotherapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SAB Biotherapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.45% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SAB Biotherapeutics has recently decreased by 8.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SAB Biotherapeutics does not currently pay a dividend.

Dividend Growth

SAB Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.45% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SAB Biotherapeutics has recently decreased by 8.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for SAB Biotherapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.77% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.82% of the stock of SAB Biotherapeutics is held by institutions.

SABS Stock Analysis - Frequently Asked Questions

How have SABS shares performed this year?

SAB Biotherapeutics' stock was trading at $3.79 on January 1st, 2025. Since then, SABS stock has decreased by 54.4% and is now trading at $1.73.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) announced its quarterly earnings data on Friday, May, 9th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.44.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SAB Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include ChargePoint (CHPT), PayPal (PYPL), Coinbase Global (COIN), Tesla (TSLA), Confluent (CFLT), CrowdStrike (CRWD) and Ford Motor (F).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SABS
• CIK: 1833214
• Web: www.bigcypressaccorp.com
• Phone: 605-679-6980
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.25
• High Stock Price Target: $20.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +665.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.10 million
• Net Margins: N/A
• Pretax Margin: -9,067.72%
• Return on Equity: -105.14%
• Return on Assets: -69.24%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.69
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 12.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 9,290,000
• Free Float: 6,709,000
• Market Cap: $16.07 million
• Optionable: Not Optionable
• Beta: 0.52